10-K: Actinium Pharmaceuticals Reports 2024 Annual Results, Highlights Pipeline Progress and Strategic Priorities

Actinium Pharmaceuticals' 2024 annual report details the company's financial results, pipeline advancements, and strategic focus on targeted radiotherapies for advanced cancers.

Summary

• Actinium Pharmaceuticals, a clinical-stage biopharmaceutical company, reported its annual results for the fiscal year ended December 31, 2024.
• The company is focused on developing targeted radiotherapies for advanced cancers, including AML and MDS.
• Actinium is advancing two clinical-stage product candidates: Actimab-A and Iomab-ACT, and a preclinical program ATNM-400.
• Actimab-A is being developed for myeloid malignancies and solid tumors, while Iomab-ACT is a targeted conditioning agent for cell and gene therapies.
• The company's strategy involves building a specialty radiotherapeutics company with capabilities across radioisotope production, manufacturing, preclinical research, and clinical development.
• Actinium is pursuing partnerships to deploy its proprietary Ac-225 cyclotron manufacturing technology.
• The company incurred a net loss of $38.2 million in 2024, compared to a net loss of $48.8 million in 2023.
• Research and development expenses decreased to $30.0 million in 2024 from $38.7 million in 2023.
• General and administrative expenses decreased to $12.1 million in 2024 from $13.3 million in 2023.
• As of March 28, 2025, Actinium had 37 full-time employees, with 22 engaged in research and development and clinical development activities.
• The company expects its existing resources to fund planned operations for more than 12 months following the report date.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there's progress in the pipeline and strategic initiatives, the company faces regulatory hurdles, ongoing losses, and the need for additional funding. The FDA's requirement for additional trials for Iomab-B is a significant setback.

Positives

• The company has aligned with the FDA on an operationally seamless Phase 2/3 trial to compare Actimab-A + CLAG-M to CLAG-M alone in patients with r/r AML.
• The NCI will serve as the regulatory sponsor for any clinical trials mutually approved by both parties to study Actimab-A, and the CRADA will provide extensive support for and accelerate the development of Actimab-A alone or in combination with chemotherapy, immunotherapy, targeted agents and other novel combinations.
• The company has secured multiple suppliers that are expected to provide cGMP Ac-225 for its planned clinical trials.
• The company has developed intellectual property, know-how and trade secrets related to the manufacturing process of Ac-225.
• The company has entered into Ac-225 supply agreement with Eckert & Ziegler, a leading specialist in isotope-related components for nuclear medicine and radiation therapy, to support its comprehensive development including U.S. and international clinical trials.

Negatives

• The company has incurred net losses in every year since its inception and anticipates that it will continue to incur net losses in the future.
• The FDA determined that the SIERRA trial alone is not adequate to support a BLA filing for Iomab-B and is requiring an additional randomized head-to-head clinical trial to demonstrate an overall survival benefit in an intent to treat population.
• The FDA is also requiring that an additional dose optimization trial demonstrating safety and efficacy be completed to calculate the dose of Iomab-B based on absorbed dose by the bone marrow, rather than the maximum tolerable dose of 24 Gy of radiation to the liver as was done in the SIERRA trial based on several interactions with the FDA prior to the start of the SIERRA trial.
• The company is seeking a strategic partner for Iomab-B in the U.S. to advance these additional trials, but there are no assurances that the additional trials will be successful or that the company can satisfy all of the FDAs requests.
• The company has limited access to the capital markets and even if it can raise additional funding, it may be required to do so on unfavorable terms.
• The company has faced delays and risks associated with reliance on key third party manufacturers in the past and may be faced with such delays and risks in the future.

Risks

• The company is a clinical-stage company and has generated no revenue from commercial sales to date.
• If the company fails to obtain additional financing, it will be unable to continue or complete its product development or product commercialization and you will likely lose your entire investment.
• The company is highly dependent on the clinical, regulatory and commercial success of Iomab-B, Actimab-A, Iomab-ACT and other pipeline candidates which it may never achieve.
• The company's business could be adversely affected by the effects of future health epidemics.
• The company's business is subject to cybersecurity risks.
• The FDA, EMA or comparable foreign regulatory authorities may disagree with the company's regulatory plans and it may fail to obtain regulatory approval of its product candidates.
• The company may be unable to obtain a sufficient supply of isotopes to support clinical development or at commercial scale.
• The company may encounter difficulties enrolling patients in its clinical trials, its clinical development activities could be delayed or otherwise adversely affected.
• The company may have conflicts with its partners that could delay or prevent the development or commercialization of its product candidates.
• The company may be subject to claims that its third-party service providers, consultants or current or former employees have wrongfully used or disclosed confidential information of third parties.
• The company is highly dependent on its key personnel, and if it is not successful in attracting and retaining highly qualified personnel, it may not be able to successfully implement its business strategy.
• Certain provisions of the company's Certificate of Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire it and make a takeover more difficult to complete, even if such a transaction were in its stockholders interest.
• The company's ability to utilize its net operating loss carryforwards and certain other tax attributes may be limited.

Future Outlook

Actinium expects its existing resources to be sufficient to fund its planned operations for more than 12 months following the date of the report. The company plans to continue advancing its clinical programs, seek strategic partnerships, and build its manufacturing capabilities.

Management Comments

• Actinium's strategy is to build a specialty radiotherapeutics company with the capabilities to produce radioisotopes, manufacture radiotherapies, conduct preclinical research, clinical development and supply radiotherapies to the point of care.
• The company believes its strategy will enable it to build a successful company with the potential for high operating efficiencies.

Industry Context

The biopharmaceutical industry is highly competitive, particularly in oncology, hematology, and cell and gene therapy. Actinium faces competition from larger pharmaceutical companies, biotechnology companies, academia, and other public and private entities.

Comparison to Industry Standards

• Pluvicto, a PSMA-targeting radiotherapy marketed by Novartis, generated sales of $1.39 billion in 2024.
• Approved CAR-T therapies generated sales of over $4.0 billion in 2024.
• PD-1 checkpoint inhibitors generated sales totaling more than $45 billion in 2024.
• Jasper Therapeutics and Magenta Therapeutics ceased development of their antibody and antibody-drug conjugate or ADC conditioning programs for BMT in malignant diseases.
• Telix Pharmaceuticals has announced plans for a conditioning program based on a CD66 radiotherapeutic approach in systemic amyloid light-chain amyloidosis (SALA) via an early-stage investigator-sponsored trial.

Legal Proceedings

• A putative class action complaint was filed against the Company and certain executives alleging material misrepresentations and omissions concerning the Iomab-B Phase 3 Sierra Trial.

Stakeholder Impact

• The company's activities impact shareholders, employees, patients, and the broader healthcare community.
• The success of clinical trials and regulatory approvals will directly affect patient access to new cancer therapies.
• The company's financial performance and strategic decisions impact shareholder value and employee opportunities.

Next Steps

• Initiate the Phase 2 portion of the Actimab-A + CLAG-M pivotal Phase 2/3 trial in 2025.
• Generate initial clinical data from the frontline AML triplet trial in the second half of 2025.
• Present initial proof of concept clinical data from the Actimab-A solid tumor program in the second half of 2025.
• Commence patient enrollment of the Iomab-ACT trial with commercial CAR-T therapy in the first half of 2025 and generate proof of concept clinical data by year end 2025.
• Commence patient enrollment for the Phase 1 trial of Iomab-ACT as targeted conditioning prior to a BMT for patients with SCD in the first half of 2025 and enroll up to 15 patients with initial safety and efficacy results from the initial cohort of patients receiving Iomab-ACT prior to a BMT for their SCD in the second half of 2025.
• Commence the build-out of a manufacturing facility in the second quarter of 2025.

Key Dates

Keywords

Actinium Pharmaceuticals, targeted radiotherapies, Actimab-A, Iomab-ACT, ATNM-400, AML, MDS, clinical trials, radiopharmaceuticals, cancer therapy